(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 4 - LGX818 for patients with BRAFV600 mutated tumors
What is the purpose of this trial?
To assess clinical benefit associated with LGX818 treatment based on local investigator assessment.
- 18 Years and older
- Novartis Pharmaceuticals
- Last Updated:
- Study HIC#: